<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460108</url>
  </required_header>
  <id_info>
    <org_study_id>EK_11_027_0311</org_study_id>
    <nct_id>NCT01460108</nct_id>
  </id_info>
  <brief_title>AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation</brief_title>
  <acronym>CV+</acronym>
  <official_title>Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and efficacy of the AeriSeal System&#xD;
      in patients with advanced upper lobe predominant emphysema and significant collateral&#xD;
      ventilation as determined by the Chartis System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator initiated, open-label, uncontrolled study to prospectively&#xD;
      characterize the safety and efficacy of the AeriSeal System in patients with advanced upper&#xD;
      lobe predominant emphysema found to have significant collateral ventilation using the Chartis&#xD;
      System.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Forced Expiratory Volume in one second (FEV1)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from baseline in FEV1 measurement after 12 weeks following completion of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in one second (FEV1).</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in FEV1 at 24 Weeks following completion of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>12 Weeks and 24 Weeks</time_frame>
    <description>Change from baseline in FVC at 12 and 24 weeks following completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio of Residual Volume to Total Lung Capacity (RV/TLC)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in RV/TLC ratio at 24 weeks following completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distance walked in six minutes (6MWT)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in 6MWT distance at 24 weeks following completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medical Research Council Dyspnea (MRCD) score</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in MRCD score at 24 weeks following completion of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life assessment (St. George's Respiratory Questionnaire)(SGRQ)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in disease-specific health related quality of life assessment (SGRQ) at 24 weeks following completion of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Collateral Ventilation</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in collateral ventilation at 24 weeks following completion of therapy as measured by the Chartis System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanticipated Serious Adverse Device Effects (USADEs)</measure>
    <time_frame>24 Week</time_frame>
    <description>Record of any/all USADEs up to 24 weeks follwoing completion of therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Emphysema</condition>
  <condition>COPD</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>AeriSeal System Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AeriSeal System</intervention_name>
    <description>20 mL</description>
    <arm_group_label>AeriSeal System Treatment</arm_group_label>
    <other_name>Emphasemateous Lung Sealant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent and to participate in the study&#xD;
&#xD;
          -  Diagnosis of advanced emphysema (GOLD Stage III or Stage IV disease)&#xD;
&#xD;
          -  Radiologic evidence of non-bullous upper lobe predominant heterogeneous emphysema with&#xD;
             at least 2 target sites deemed appropriate for treatment evident by CT imaging&#xD;
&#xD;
          -  DLco between 20 and 60% predicted&#xD;
&#xD;
          -  Positive Collateral Ventilation as determined by the Chartis® System&#xD;
&#xD;
          -  Clinically significant dyspnea (defined as a MRC dyspnea score of 2 or greater at&#xD;
             Screening)&#xD;
&#xD;
          -  Failure of standard medical therapy to provide adequate relief of symptoms (defined as&#xD;
             regular use of standard medication for more than 1 month prior to Screening; standard&#xD;
             medications include at least an inhaled beta agonist and inhaled anticholinergic&#xD;
             unless medically contraindicated or prior medical failure)&#xD;
&#xD;
          -  Significant airflow obstruction as demonstrated by Spirometry 15 minutes after&#xD;
             administration of bronchodilator with:&#xD;
&#xD;
          -  5% &lt; FEV1 &lt; 50% predicted using the ATS recommended calculation for expected value&#xD;
&#xD;
          -  FEV1/FVC ratio &lt;70%&#xD;
&#xD;
          -  Physiological evidence of hyperinflation with Lung volumes (plethysmographic) of:&#xD;
&#xD;
          -  TLC &gt; 100% predicted using the ATS recommended calculation for expected value&#xD;
&#xD;
          -  RV &gt; 135% predicted using the ATS recommended calculation for expected value&#xD;
&#xD;
          -  Six-Minute Walk Test distance ≥ 150 m&#xD;
&#xD;
          -  Abstinence from inhaled tobacco use for at least 16 weeks prior to the initial&#xD;
             Screening visit until the end of the study&#xD;
&#xD;
          -  Female patients are either post-menopausal or surgically sterile. Women with&#xD;
             child-bearing potential will not be included in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alpha-1 antitrypsin serum level of &lt; 80 mg/dL (i.e. &lt; 11 micro mol/L) at Screening&#xD;
&#xD;
          -  Body mass index &lt; 15 kg/m2 or &gt; 35 kg/m&#xD;
&#xD;
          -  Clinically significant asthma, chronic bronchitis or bronchiectasis as determined by&#xD;
             the Investigator, or a significant COPD exacerbation within the past 4 months&#xD;
&#xD;
          -  Use of systemic steroids &gt; 20 mg/day or equivalent immunosuppressive agents, heparins,&#xD;
             oral anticoagulants (e.g., warfarin, dicumarol; note: antiplatelet drugs including&#xD;
             aspirin and clopidogrel are permitted) or investigational medications within 4 weeks&#xD;
             of Screening&#xD;
&#xD;
          -  Allergy or sensitivity to medications required to safely perform AeriSeal System&#xD;
             treatment under general anesthesia or conscious sedation&#xD;
&#xD;
          -  Participation in an investigational study of a drug, biologic, or device not currently&#xD;
             approved for marketing within 30 days prior to the Screening visit&#xD;
&#xD;
          -  Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, prior lung&#xD;
             transplantation, prior airway stent placement, prior pleurodesis, or prior&#xD;
             endobronchial lung volume reduction therapy of any type&#xD;
&#xD;
          -  Significant co-morbidity that carries prohibitive risks (e.g., HIV/AIDS, cancer) or is&#xD;
             associated with less than 2-year expected survival&#xD;
&#xD;
          -  Blood gases and oxygen saturation:&#xD;
&#xD;
               -  SpO2 ≤ 90% on &gt; 4 L/min supplemental O2, at rest&#xD;
&#xD;
               -  PaCO2 ≥ 55mmHg&#xD;
&#xD;
               -  DLCO &lt; 20% or &gt; 60% predicted for patients with heterogeneous emphysema&#xD;
&#xD;
          -  Chest CT scan: Presence of any of the following radiologic abnormalities:&#xD;
&#xD;
               -  Pulmonary nodule on CT scan greater than 1.0 cm in diameter (Does not apply if&#xD;
                  present for 2 years or more without increase in size or if proven benign by&#xD;
                  biopsy/PET)&#xD;
&#xD;
               -  Giant Bullous Disease&#xD;
&#xD;
               -  Radiologic picture consistent with active pulmonary infection, e.g., unexplained&#xD;
                  parenchymal infiltrate&#xD;
&#xD;
               -  Significant interstitial lung disease (based upon investigator judgment)&#xD;
&#xD;
               -  Significant pleural disease (based upon investigator judgment)&#xD;
&#xD;
               -  Any condition that the Investigator believes would interfere with the intent of&#xD;
                  the study or would make participation not in the best interest of the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arschang Valipour, MD, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Boltzmann-Institut für COPD und Pneumologische Epidemiologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arschang Valipour, MD, FCCP</last_name>
    <phone>43-1-91060-41008</phone>
    <email>arschang.valipour@wienkav.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Otto-Wagner-Spital</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arschang Valipour, MD, FCCP</last_name>
      <phone>43-1-91060-41008</phone>
      <email>arschang.valipour@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Arschang Valipour, MD, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2011</study_first_posted>
  <last_update_submitted>October 26, 2011</last_update_submitted>
  <last_update_submitted_qc>October 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology</investigator_affiliation>
    <investigator_full_name>Arschang Valipour</investigator_full_name>
    <investigator_title>Ass. Prof. Department of Respiratory and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>PLVR</keyword>
  <keyword>AeriSeal</keyword>
  <keyword>Treatment</keyword>
  <keyword>Device</keyword>
  <keyword>Breathing</keyword>
  <keyword>COPD</keyword>
  <keyword>emphysema</keyword>
  <keyword>polymeric lung volume reduction</keyword>
  <keyword>heterogeneous</keyword>
  <keyword>homogeneous</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

